¸ÂÃãÇü ÀÇ·á ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå : À¯Çüº°, ¿ëµµº°, ÃÖÁ¾»ç¿ëÀÚº°, Áö¿ªº°
Personalized Medicine Biomarkers Market, By Type, By Application, By End User, By Geography
»óǰÄÚµå : 1629643
¸®¼­Ä¡»ç : Coherent Market Insights
¹ßÇàÀÏ : 2024³â 12¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹®
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,500 £Ü 6,511,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 7,000 £Ü 10,128,000
PDF (Multi User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 7¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 10,000 £Ü 14,469,000
PDF (Enterprise User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¼¼°è ¸ÂÃãÇü ÀÇ·á ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀåÀº 2024³â 247¾ï ´Þ·¯·Î ÃßÁ¤µÇ¸ç, 2024³âºÎÅÍ 2031³â±îÁö 15.6%ÀÇ CAGRÀ» ±â·ÏÇØ 2031³â¿¡´Â 681¾ï 1,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

º¸°í¼­ ¹üÀ§ º¸°í¼­ »ó¼¼
±âÁØ ¿¬µµ 2023³â 2024³â ½ÃÀå ±Ô¸ð 247¾ï ´Þ·¯
½ÇÀû µ¥ÀÌÅÍ 2019-2023³â ¿¹Ãø ±â°£ 2024-2031³â
¿¹Ãø ±â°£ 2024-2031³â CAGR: 15.60% 2031³â °¡Ä¡ ¿¹Ãø 681¾ï 1,000¸¸ ´Þ·¯
±×¸². ¸ÂÃãÇü ÀÇ·á ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå Á¡À¯À²(%), Áö¿ªº°, 2024³â
Personalized Medicine Biomarkers Market-IMG1

¸ÂÃãÇü ÀÇ·á ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀåÀ̶õ À¯ÀüÀÚ Á¤º¸¸¦ Ȱ¿ëÇØ ȯÀÚ¿¡°Ô ÃÖÀûÀÇ Ä¡·á¸¦ °èȹÇÏ´Â °ÍÀ» ¸»ÇÕ´Ï´Ù. ¸ÂÃãÇü ÀÇ·á´Â ¿¹ÃøµÇ´Â Áúº´¿¡ ´ëÇÑ ¼ÒÀÎ µî °³ÀÎÀÇ Æ¯¼º¿¡ ¸Â´Â ¿¹¹æ¾àÀ̳ª Ä¡·áÁ¦¸¦ ¼³°èÇÏ´Â °ÍÀ» ¸ñÀûÀ¸·Î ÇÕ´Ï´Ù. ¹ÙÀÌ¿À¸¶Ä¿´Â ¾î¶² ȯÀÚ°¡ ƯÁ¤ Ä¡·á¿¡ ÀûÇÕÇÑÁö ÆÄ¾ÇÇÏ´Â µ¥ µµ¿òÀÌ µÇ±â ¶§¹®¿¡ ¸ÂÃãÇü ÀÇ·á¿¡¼­ Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. ¹ÙÀÌ¿À¸¶Ä¿´Â Áúº´À» ¼±º°Çϰí, Áúº´ ¹ßº´ À§ÇèÀ» ½Äº°Çϰí, Áúº´ ÁøÇà ¼Óµµ¸¦ ¿¹ÃøÇϰí, Ä¡·á¿¡ ´ëÇÑ ¹ÝÀÀ¼ºÀ» Æò°¡ÇÏ´Â µ¥ »ç¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. À¯ÀüÀÚ °Ë»çÀÇ °¡¿ë¼º Áõ°¡, ¸¸¼ºÁúȯÀÇ À¯º´·ü Áõ°¡, Á¤¹Ð ÀÇ·á¿¡ ´ëÇÑ °ü½É Áõ°¡, ±â¼ú ¹ßÀüÀº ¼¼°è ¸ÂÃãÇü ÀÇ·á ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀåÀÇ ¼ºÀåÀ» ÃËÁøÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÁÖ¿ä ¿äÀÎ Áß ÀϺÎÀÔ´Ï´Ù.

½ÃÀå ¿ªÇÐ:

¼¼°è ¸ÂÃãÇü ÀÇ·á ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀåÀÇ ¼ºÀåÀº Àü ¼¼°è ¸¸¼ºÁúȯ ¹× »ý¸íÀ» À§ÇùÇÏ´Â Áúº´ÀÇ À¯º´·ü Áõ°¡, Á¦¾àȸ»çÀÇ R&D ÀÌ´Ï¼ÅÆ¼ºê Áõ°¡, ½Å¾à°³¹ß ¹× ½Å¾à°³¹ß¿¡ ¹ÙÀÌ¿À¸¶Ä¿ Àû¿ë Áõ°¡, Á¤¹ÐÀÇ·á¿¡ ´ëÇÑ °ü½É Áõ°¡, ¹ÙÀÌ¿À¸¶Ä¿ ½Äº° ±â¼ú ¹ßÀü, À¯ÀüÀÚ °Ë»ç °¡¿ë¼º µî ¿©·¯ ¿äÀο¡ ÀÇÇØ ÃËÁøµÇ°í ÀÖ½À´Ï´Ù. ±×·¯³ª ¹ÙÀÌ¿À¸¶Ä¿ ±â¹Ý °Ë»ç¿Í °ü·ÃµÈ ³ôÀº ºñ¿ë°ú »óȯ Á¤Ã¥ÀÇ ºÎÁ·Àº ½ÃÀå ¼ºÀåÀ» ÀúÇØÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ½ÅÈï °æÁ¦±¹¿¡¼­´Â ÀÇ·áºñ Áõ°¡, ¸ÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ ÀÎ½Ä Áõ°¡, ÀÇ·á ¿¬±¸ º¸Á¶±Ý Áõ°¡ µîÀ¸·Î ÀÎÇØ ½ÃÀå °³¹ß ±âȸ°¡ Å©°Ô È®´ëµÇ°í ÀÖ½À´Ï´Ù. ½ÅÁ¦Ç° Ãâ½Ã, ½ÃÀå ÁøÀÔ ±â¾÷ ¹× ¿¬±¸±â°ü°úÀÇ Á¦ÈÞ, ±â¾÷ÀÇ Áö¸®Àû È®Àå Àü·« µîÀº ¼¼°è ¸ÂÃãÇü ÀÇ·á ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå¿¡¼­ ÁÖ¿ä ºñÁî´Ï½º ±âȸ·Î ÀÛ¿ëÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.

º» Á¶»çÀÇ ÁÖ¿ä Æ¯Â¡

ÀÌ º¸°í¼­´Â 2023³âÀ» ±âÁØ ¿¬µµ·Î ÇÏ¿© ¿¹Ãø ±â°£(2024-2031³â)ÀÇ ½ÃÀå ±Ô¸ð¿Í ¿¬Æò±Õ ¼ºÀå·ü(CAGR)À» Á¦°øÇÏ´Â ¼¼°è ¸ÂÃãÇü ÀÇ·á¿ë ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀåÀ» »ó¼¼È÷ ºÐ¼®ÇÏ¿© ¿¹ÃøÇÑ º¸°í¼­ÀÔ´Ï´Ù.

¶ÇÇÑ, ´Ù¾çÇÑ ºÎ¹®¿¡ °ÉÄ£ ÀáÀçÀû ¼öÀÍ ±âȸ¸¦ ¹àÈ÷°í, ÀÌ ½ÃÀåÀÇ ¸Å·ÂÀûÀÎ ÅõÀÚ Á¦¾È ¸ÅÆ®¸¯½º¸¦ ¼³¸íÇÕ´Ï´Ù.

¶ÇÇÑ ½ÃÀå ÃËÁø¿äÀÎ, ¾ïÁ¦¿äÀÎ, ±âȸ, ½ÅÁ¦Ç° Ãâ½Ã ¹× ½ÂÀÎ, ½ÃÀå µ¿Çâ, Áö¿ªº° Àü¸Á, ÁÖ¿ä ±â¾÷ÀÇ °æÀï Àü·« µî¿¡ ´ëÇÑ Áß¿äÇÑ °í·Á»çÇ×µµ Á¦°øÇÕ´Ï´Ù.

ÀÌ º¸°í¼­ÀÇ ÁÖ¿ä Á¶»ç ´ë»ó ±â¾÷À¸·Î´Â F Roche Diagnostics, Illumina, Inc., Thermo Fisher Scientific Inc., QIAGEN N.V., Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., Siemens Healthineers, Abbott Laboratories, Merck KGaA, Genomic Health, Inc., Myriad Genetics, Inc., Foundation Medicine, Inc., Exact Sciences Corporation, Guardant Health, Inc., Luminex Corporation µîÀÌ ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­ÀÇ ÀλçÀÌÆ®¸¦ ÅëÇØ ¸¶ÄÉÆÃ ´ã´çÀÚ¿Í ±â¾÷ °æ¿µÁøÀº ÇâÈÄ Á¦Ç° Ãâ½Ã, À¯ÇüÈ­, ½ÃÀå È®´ë ¹× ¸¶ÄÉÆÃ Àü·«¿¡ ´ëÇÑ Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖ½À´Ï´Ù.

¼¼°è ¸ÂÃãÇü ÀÇ·á ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå º¸°í¼­´Â ÅõÀÚÀÚ, °ø±Þ¾÷ü, Á¦Ç° Á¦Á¶¾÷ü, À¯Åë¾÷ü, ½Å±Ô ÁøÀÔÀÚ, À繫 ºÐ¼®°¡ µî ¾÷°èÀÇ ´Ù¾çÇÑ ÀÌÇØ°ü°èÀÚ¸¦ ´ë»óÀ¸·Î ÇÕ´Ï´Ù.

¼¼°è ¸ÂÃãÇü ÀÇ·á ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå ºÐ¼®¿¡ »ç¿ëµÇ´Â ´Ù¾çÇÑ Àü·« ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ÀÌÇØ°ü°èÀÚµéÀº ÀÇ»ç°áÁ¤À» ½±°Ô ³»¸± ¼ö ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¸ñÀû°ú °¡Á¤

Á¦2Àå ½ÃÀå Àü¸Á

Á¦3Àå ½ÃÀå ¿ªÇÐ, ±ÔÁ¦, µ¿Ç⠺м®

Á¦4Àå ¼¼°èÀÇ ¸ÂÃãÇü ÀÇ·á ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå, À¯Çüº°, 2019-2031³â

Á¦5Àå ¼¼°èÀÇ ¸ÂÃãÇü ÀÇ·á ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå, ¿ëµµº°, 2019-2031³â

Á¦6Àå ¼¼°èÀÇ ¸ÂÃãÇü ÀÇ·á ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå, ÃÖÁ¾»ç¿ëÀÚº°, 2019-2031³â

Á¦7Àå ¼¼°èÀÇ ¸ÂÃãÇü ÀÇ·á ¹ÙÀÌ¿À¸¶Ä¿ ½ÃÀå, Áö¿ªº°, 2019-2031³â

Á¦8Àå °æÀï ±¸µµ

Á¦9Àå ¾Ö³Î¸®½ºÆ®ÀÇ Ãßõ»çÇ×

Á¦10Àå Âü°í¹®Çå°ú Á¶»ç ¹æ¹ý

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global personalized medicine biomarkers market is estimated to be valued at USD 24.70 Bn in 2024 and is expected to reach USD 68.11 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 15.6% from 2024 to 2031.

Report Coverage Report Details
Base Year: 2023 Market Size in 2024: US$ 24.70 Bn
Historical Data for: 2019 To 2023 Forecast Period: 2024 To 2031
Forecast Period 2024 to 2031 CAGR: 15.60% 2031 Value Projection: US$ 68.11 Bn
Figure. Personalized Medicine Biomarkers Market Share (%), By Region 2024
Personalized Medicine Biomarkers Market - IMG1

Personalized medicine biomarkers market refers to the utilization of genetic information to plan the most suitable treatment for patients. Personalized medicine aims to design preventive or therapeutic products tailored to an individual's characteristics, including their predicted predisposition to illness. Biomarkers play an important role in personalized medicine as they help identify which patients are suitable for specific treatments. Biomarkers can be utilized to screen for diseases, identify the risk of developing a disease, predict the rate of disease progression, and assess the response to treatment. Increasing availability of genetic tests, growing prevalence of chronic diseases, rising focus on precision medicine, and technological advancements are some of the key factors expected to propel the growth of the global personalized medicine biomarkers market.

Market Dynamics:

Global personalized medicine biomarkers market growth is driven by several factors such as growing prevalence of chronic and life-threatening diseases worldwide, rising R&D initiatives by pharmaceutical companies, increasing application of biomarkers in drug discovery and development, growing focus on precision medicine, technological advancements in biomarker identification, and availability of genetic tests. However, high costs associated with biomarker-based tests and lack of reimbursement policies are expected to restrain the market growth. The market players have significant opportunities in developing economies owing to growing healthcare expenditure, rising awareness about personalized medicine, and increasing healthcare research grants. New product launches, collaborations between market players and research institutes, and geographical expansion strategies by companies are some key opportunities in the global personalized medicine biomarkers market.

Key Features of the Study:

This report provides in-depth analysis of the global personalized medicine biomarkers market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players

Key companies covered as a part of this study include F Roche Diagnostics, Illumina, Inc., Thermo Fisher Scientific Inc., QIAGEN N.V., Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., Siemens Healthineers, Abbott Laboratories, Merck KGaA, Genomic Health, Inc., Myriad Genetics, Inc., Foundation Medicine, Inc., Exact Sciences Corporation, Guardant Health, Inc., and Luminex Corporation

Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics

The global personalized medicine biomarkers market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global personalized medicine biomarkers market

Market Segmentation

Table of Contents

1. Research Objectives and Assumptions

2. Market Purview

3. Market Dynamics, Regulations, and Trends Analysis

4. Global Personalized Medicine Biomarkers Market, By Type, 2019-2031, (USD Bn)

5. Global Personalized Medicine Biomarkers Market, By Application, 2019-2031, (USD Bn)

6. Global Personalized Medicine Biomarkers Market, By End User, 2019-2031, (USD Bn)

7. Global Personalized Medicine Biomarkers Market, By Region, 2019 - 2031, Value (USD Bn)

8. Competitive Landscape

9. Analyst Recommendations

10. References and Research Methodology

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â